Biosimilar drugs underutilized due to commercial insurance restrictions
Biosimilars provide the same therapeutic benefits at much less cost than biologic medications, but a first-of-its-kind survey led by USC Leonard D. Schaeffer Center for Health Policy and Economics shows that commercial insurers either exclude or limit … Read More »